Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › Shining-1 (T2D)

Shining-1 (T2D)

RAY1225 · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
RAY1225
Population
t2d
Phase
2
Participants
231
Duration
24 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
RAY1225 15 mg every 2 weekst2d china24———−2.8 vs −0.2—————−7.8 vs +0.0verified
3 mg Q2Wt2d china24231——−1.7 vs −0.2——————congress
6 mg Q2Wt2d china24231——−2.0 vs −0.2——————congress
9 mg Q2Wt2d china24231——−2.1 vs −0.2——————congress
12 mg Q2Wt2d china24231——−2.3 vs −0.2——————congress

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (5)
  • RAY1225 15 mg every 2 weeks · hba1c · Abstract, Results
    -2.76% (-3.25 to -2.26) in the 3 mg, 6mg, 9mg, 12mg and 15 mg, respectively
  • 3 mg Q2W · hba1c · abstract
    The changes in HbA1c from baseline to week 24 were -1.66% (95% CI -1.88 to -1.45), -2.04% (-2.26 to -1.82), -2.14% (-2.36 to -
  • 6 mg Q2W · hba1c · abstract
    The changes in HbA1c from baseline to week 24 were -1.66% (95% CI -1.88 to -1.45), -2.04% (-2.26 to -1.82), -2.14% (-2.36 to -
  • 9 mg Q2W · hba1c · abstract
    The changes in HbA1c from baseline to week 24 were -1.66% (95% CI -1.88 to -1.45), -2.04% (-2.26 to -1.82), -2.14% (-2.36 to -
  • 12 mg Q2W · hba1c · abstract
    1.92) , -2.34% (-2.56 to -2.12), -2.76% (-3.25 to -2.26) in the 3 mg, 6mg, 9mg, 12mg and 15 mg, respectively, versus -0.25% (-0.43 to -0.07)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Shining-1 (T2D). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/shining-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.